Cell Source, Inc. (CLCS) Financial Statements (2023 and Earlier)
Company Profile
| Business Address |
57 WEST 57TH STREET NEW YORK, NY 10019 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 599 | 82 | 245 | 55 | 1 | 17 | |||
| Cash and cash equivalents | 599 | 82 | 245 | 55 | 1 | 17 | |||
| Prepaid expense | 244 | 215 | 174 | 178 | 135 | 47 | 86 | ||
| Other current assets | 17 | 8 | 42 | 30 | 20 | 35 | 29 | ||
| Total current assets: | 861 | 305 | 216 | 452 | 210 | 82 | 132 | ||
| Noncurrent Assets | |||||||||
| Restricted cash and investments | 4 | 103 | |||||||
| Total noncurrent assets: | 4 | 103 | |||||||
| TOTAL ASSETS: | 861 | 309 | 319 | 452 | 210 | 82 | 132 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,345 | 1,956 | 2,122 | 2,182 | 1,645 | 1,392 | 1,681 | ||
| Accounts payable | 285 | 340 | 152 | 193 | 376 | 446 | 313 | ||
| Accrued liabilities | 950 | 696 | 1,106 | 1,160 | 1,038 | 947 | 1,145 | ||
| Employee-related liabilities | 0 | 0 | 10 | ||||||
| Taxes payable | 122 | ||||||||
| Interest and dividends payable | 1,109 | 920 | 863 | 697 | 230 | 223 | |||
| Debt | 1,159 | 1,038 | 1,138 | 1,238 | 1,013 | 1,113 | 1,113 | ||
| Deferred compensation liability | 761 | 749 | 719 | 724 | |||||
| Due to related parties | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||
| Other liabilities | 226 | 231 | 236 | ||||||
| Other undisclosed current liabilities | 6,634 | 4,105 | 4,196 | 3,724 | 3,210 | ||||
| Total current liabilities: | 11,049 | 3,894 | 4,129 | 8,400 | 7,229 | 6,610 | 6,390 | ||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 6,442 | 5,229 | |||||||
| Total liabilities: | 11,049 | 10,335 | 9,358 | 8,400 | 7,229 | 6,610 | 6,390 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (10,188) | (10,027) | (9,039) | (7,947) | (7,018) | (6,528) | (6,258) | ||
| Preferred stock | 1 | 1 | |||||||
| Common stock | 34 | 33 | 33 | 33 | 30 | 30 | 27 | ||
| Additional paid in capital | 20,120 | 18,482 | 18,158 | 17,725 | 17,382 | 16,565 | 15,673 | ||
| Accumulated deficit | (30,343) | (28,544) | (27,231) | (25,706) | (24,432) | (23,124) | (21,960) | ||
| Other undisclosed stockholders' equity attributable to parent | 2 | 1 | 1 | 1 | 1 | ||||
| Total stockholders' equity: | (10,188) | (10,027) | (9,039) | (7,947) | (7,018) | (6,528) | (6,258) | ||
| TOTAL LIABILITIES AND EQUITY: | 861 | 309 | 319 | 452 | 210 | 82 | 132 | ||
Income Statement (P&L) ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (1,315) | (995) | (1,121) | (836) | (1,166) | (903) | (733) | |
| Operating loss: | (1,315) | (995) | (1,121) | (836) | (1,166) | (903) | (733) | |
| Nonoperating expense | (484) | (318) | (403) | (438) | (142) | (261) | (80) | |
| Interest and debt expense | (214) | (163) | (306) | (2) | (212) | 78 | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (134) | |||||||
| Loss from continuing operations before income taxes: | (2,014) | (1,476) | (1,831) | (1,408) | (1,309) | (1,377) | (736) | |
| Other undisclosed income from continuing operations | 2,424 | |||||||
| Income (loss) before gain (loss) on sale of properties: | (2,014) | (1,476) | (1,831) | 1,016 | (1,309) | (1,377) | (736) | |
| Other undisclosed net income (loss) | 214 | 163 | 306 | 134 | 2 | 212 | (78) | |
| Net income (loss): | (1,800) | (1,313) | (1,525) | 1,150 | (1,308) | (1,165) | (814) | |
| Other undisclosed net loss attributable to parent | (2,424) | |||||||
| Net loss attributable to parent: | (1,800) | (1,313) | (1,525) | (1,274) | (1,308) | (1,165) | (814) | |
| Preferred stock dividends and other adjustments | (246) | (226) | (223) | |||||
| Other undisclosed net loss available to common stockholders, basic | (228) | (226) | (212) | (211) | ||||
| Net loss available to common stockholders, diluted: | (2,046) | (1,539) | (1,748) | (1,502) | (1,534) | (1,377) | (1,025) | |
Comprehensive Income ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,800) | (1,313) | (1,525) | 1,150 | (1,308) | (1,165) | (814) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (1,800) | (1,313) | (1,525) | 1,150 | (1,308) | (1,165) | (814) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.